fbpx

Day: March 29, 2018

Prevalence of Autoimmune Diseases & the Market for LDN.

Low Dose Naltrexone (LDN) holds the potential to help millions of people suffering from various autoimmune diseases, cancers and chronic pain, find relief. Accumulating evidence suggests that LDN can stimulate the immune system and reduce autoimmune and cancer processes. Since lower doses of Naltrexone are not commercially available, LDN is available only by prescription from compounding …

Prevalence of Autoimmune Diseases & the Market for LDN.Read More »